Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1314 in Graves' Orbitopathy
NCT05394857Phase 2Terminated
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Sep 2022
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vunakizumab in Graves Orbitopathy (GO), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoint: Proptosis Responder Rate at 16 weeks. Started Sep 2022; status: terminated.
02
Drugs
vunakizumab
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on NCT05394857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05394857.